Roberto Herrera
Overview
Explore the profile of Roberto Herrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gutierrez L, Vielot N, Herrera R, Reyes Y, Toval-Ruiz C, Blandon P, et al.
PLoS Negl Trop Dis
. 2024 Nov;
18(11):e0012230.
PMID: 39527625
Background: Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and...
2.
Kutuk T, Kotecha R, Herrera R, Wieczorek D, Fellows Z, Chaswal V, et al.
Brachytherapy
. 2024 Aug;
23(6):751-760.
PMID: 39098499
Purpose: Surgically targeted radiation therapy (STaRT) with Cesium-131 seeds embedded in a collagen tile is a promising treatment for recurrent brain metastasis. In this study, the biological effective doses (BED)...
3.
Mills M, Kotecha R, Herrera R, Kutuk T, Fahey M, Wuthrick E, et al.
Clin Transl Radiat Oncol
. 2024 Jan;
45:100719.
PMID: 38292332
Purpose: While dose escalation is associated with improved local control (LC) for adrenal gland metastases (AGMs), the proximity of gastrointestinal (GI) organs-at-risk (OARs) limits the dose that can be safely...
4.
Barsky A, George J, Wroe A, Mittauer K, Kaiser A, Herrera R, et al.
Med Dosim
. 2023 Nov;
49(2):121-126.
PMID: 38001010
Advances in radiotherapy (RT) technologies permit significant decreases in the dose delivered to organs at risk (OARs) for patients with esophageal cancer (EC). Novel RT modalities such as proton beam...
5.
Kutuk T, Tolakanahalli R, Chaswal V, Yarlagadda S, Herrera R, Appel H, et al.
Brachytherapy
. 2023 Sep;
22(6):872-881.
PMID: 37722990
Purpose: This study evaluates the outcomes of recurrent brain metastasis treated with resection and brachytherapy using a novel Cesium-131 carrier, termed surgically targeted radiation therapy (STaRT), and compares them to...
6.
La Rosa A, Mittauer K, Rzepczynski A, Chuong M, Kutuk T, Bassiri N, et al.
Med Dosim
. 2023 Mar;
48(3):127-133.
PMID: 36966049
For patients with newly diagnosed glioblastoma, the current standard-of-care includes maximal safe resection, followed by concurrent chemoradiotherapy and adjuvant temozolomide, with tumor treating fields. Traditionally, diagnostic imaging is performed pre-...
7.
Hall M, Mittauer K, Herrera R, Von Werne K, Kotecha R, Kalman N, et al.
Front Oncol
. 2023 Jan;
12:1037674.
PMID: 36713501
Purpose/objectives: Magnetic resonance-guided radiotherapy (MRgRT) is increasingly used in a variety of adult cancers. To date, published experience regarding the use of MRgRT in pediatric patients is limited to two...
8.
Bryant J, Palm R, Herrera R, Rubens M, Hoffe S, Kim D, et al.
Cancer Control
. 2023 Jan;
30:10732748221150228.
PMID: 36598464
Purpose: Treatment options for pancreatic ductal adenocarcinoma (PDAC) are commonly limited for patients with advanced age due to medical comorbidities and/or poor performance status. These patients may not be candidates...
9.
Chuong M, Herrera R, Ucar A, Aparo S, De Zarraga F, Asbun H, et al.
Adv Radiat Oncol
. 2022 Dec;
8(1):101084.
PMID: 36483070
Purpose: Nearly all patients with pancreatic ductal adenocarcinoma (PDAC) eventually die of progressive cancer after exhausting treatment options. Although distant metastases (DMs) are a common cause of death, autopsy studies...
10.
Herrera R, Haq I, Anavekar N
Mayo Clin Proc
. 2022 Oct;
97(10):1936-1941.
PMID: 36202499
No abstract available.